Page 66 - MemoriaBBN-Eng
P. 66




RESEARCH GROUPS




í

á

á

ñ
í
éó

í
ñí

ó

óÓÁ


é





PROGRAMME:
Research Group in Biomedical Applications of Nuclear 
Bioengineering 
and Medical Imaging
Magnetic Resonance (GABRMN-UAB)
ú





Group Members
Lead Researcher

STAFF MEMBERS
Ars Caraltó, Carles

Candiota Silveira, Ana Paula 
Garca Chacn, Alina 
Contact:
Juli Sap, Ma Margarita
Universidad Autonoma de Barcelona. è
ASSOCIATED MEMBERS
Edifici C (Facultat Biocincies) Campus UAB. 2a Planta. 
E.mail: [email protected] Acebes Martn, Juan Jos 
http://gabrmn.uab.es/
Aguilera Grijalvo, Carlos 

Arias Ramos, Nuria 
Baquero Munera, Miguel 
Main lines of research
Cabaas Egaa, Miquel 
Capdevila Cirera, Antonio 
The major research interest of our group is the improvement of non-invasive 
Cos Domingo, Mnica 
diagnosis and prognosis of anomalous brain masses by nuclear magnetic 
Ferrer Font, Laura 
Godino Martnez, scar resonance (NMR), as well as the development of non-invasive therapy res- 
ponse monitoring tools for cerebral tumors. Within this major goal, several 
Lope Piedrafita, Silvia 
Majs Torro, Carlos sublines with connections to the MR methodology or other pathologies are 

Mart Sitjar De Togores, Juana being investigated, which include:
Moreno Torres, ngel • Characterization of the type and grade of human brain tumors and other 

Oriol Rocafiguera, Alberto neural pathologies by imaging (MRI) and in vivo magnetic resonance spec- 13
Vellido Alcacena, Alfredo
20
troscopy (MRS, MRSI).
T 
R
CONTRIBUTORS
• Classifier development and their implementation into decision-support PO
Ciezka, Magdalena systems (DSS) for helping in clinical decision making in an evidence-based E
L R
Davila Huerta, Myriam medicine context.
A
Fernndez Coello, Alejandro NU
• Search for molecular biomarkers of in vivo tumor progression/therapy res- N
Ortega Martorell, Sandra
 A
ponse with the help of ex vivo and in vitro studies of cell models, animal  /
models and their biopsies.
BN
B
R-
• In vivo molecular phenotyping of tumor progression and therapy response.
BE
CI

66







   64   65   66   67   68